Rayjean J. Hung,Cornelia M. Ulrich,Ellen L. Goode,Yonathan Brhane,Kenneth Muir,Andrew T. Chan,Loic Le Marchand,Joellen Schildkraut,John S. Witte,Rosalind Eeles,Paolo Boffetta,Margaret R. Spitz,Julia G. Poirier,David N. Rider,Brooke L. Fridley,Zhihua Chen,Christopher Haiman,Fredrick Schumacher,Douglas F. Easton,Maria Teresa Landi,Paul Brennan,Richard Houlston,David C. Christiani,John K. Field,Heike Bickeboeller,Angela Risch,Zsofia Kote-Jarai,Fredrik Wiklund,Henrik Gronberg,Stephen Chanock,Sonja I. Berndt,Peter Kraft,Sara Lindstrom,Ali Amin Al Olama,Honglin Song,Catherine Phelan,Nicholas Wentzensen,Ulrike Peters,Martha L. Slattery,Thomas A. Sellers,Graham Casey,Stephen B. Gruber,David J. Hunter,Christopher I. Amos,Brian Henderson

Abstract:BACKGROUND:Inflammation has been hypothesized to increase the risk of cancer development as an initiator or promoter, yet no large-scale study of inherited variation across cancer sites has been conducted.METHODS:We conducted a cross-cancer genomic analysis for the inflammation pathway based on 48 genome-wide association studies within the National Cancer Institute GAME-ON Network across five common cancer sites, with a total of 64 591 cancer patients and 74 467 control patients. Subset-based meta-analysis was used to account for possible disease heterogeneity, and hierarchical modeling was employed to estimate the effect of the subcomponents within the inflammation pathway. The network was visualized by enrichment map. All statistical tests were two-sided.RESULTS:We identified three pleiotropic loci within the inflammation pathway, including one novel locus in Ch12q24 encoding SH2B3 (rs3184504), which reached GWAS significance with a P value of 1.78 x 10(-8), and it showed an association with lung cancer (P = 2.01 x 10(-6)), colorectal cancer (GECCO P = 6.72x10(-6); CORECT P = 3.32x10(-5)), and breast cancer (P = .009). We also identified five key subpathway components with genetic variants that are relevant for the risk of these five cancer sites: inflammatory response for colorectal cancer (P = .006), inflammation related cell cycle gene for lung cancer (P = 1.35x10(-6)), and activation of immune response for ovarian cancer (P = .009). In addition, sequence variations in immune system development played a role in breast cancer etiology (P = .001) and innate immune response was involved in the risk of both colorectal (P = .022) and ovarian cancer (P = .003).CONCLUSIONS:Genetic variations in inflammation and its related subpathway components are keys to the development of lung, colorectal, ovary, and breast cancer, including SH2B3, which is associated with lung, colorectal, and breast cancer.

Supplementary Table 1 from Multistage Analysis of Variants in the Inflammation Pathway and Lung Cancer Risk in Smokers

Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Materials 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Figures 1 - 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Tables 1 - 3 from Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study

Additional File 1 of Integration of Single-Cell Regulon Atlas and Multi-Omics Data for Prognostic Stratification and Personalized Treatment Prediction in Human Lung Adenocarcinoma

Integration of Multiomic Annotation Data to Prioritize and Characterize Inflammation and Immune-Related Risk Variants in Squamous Cell Lung Cancer

Supplementary Tables 1-7 from Cumulative Effect of Multiple Loci on Genetic Susceptibility to Familial Lung Cancer

Supplementary Table 1-3 from MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early-Stage Non–Small Cell Lung Cancer Patients

Variants in Inflammation Genes Are Implicated in Risk of Lung Cancer in Never Smokers Exposed to Second-Hand Smoke.

Supplementary Table 8 from Smoking Modifies Pancreatic Cancer Risk Loci on 2Q21.3

Supplemental Tables for Publication from Glycemic Index, Glycemic Load, and Lung Cancer Risk in Non-Hispanic Whites

Supplementary Table 1 from Fine-mapping of the 5p15.33, 6P22.1-P21.31, and 15q25.1 Regions Identifies Functional and Histology-Specific Lung Cancer Susceptibility Loci in African-Americans

Systematic Evaluation Of Genetic Variants In The Inflammation Pathway And Risk Of Lung Cancer

Table S4 from Exploring the Complex Relationship Between Gut Microbiota and Risk of Colorectal Neoplasia Using Bidirectional Mendelian Randomization Analysis

Single Nucleotide Polymorphisms of 8 Inflammation‐related Genes and Their Associations with Smoking‐related Cancers

Supplementary Figure 1 from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer

Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response

Data from Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study